The Drug Deal Disclosure Act requires the Department of Health and Human Services to publicly release all documents, communications, contracts, and agreements related to drug pricing deals made between the federal government and pharmaceutical manufacturers since January 20, 2025. The bill specifically targets agreements involving most-favored-nation pricing (where drug prices reference international rates), direct-to-consumer drug sales, import duty exemptions, domestic investment commitments, and other special arrangements with major pharmaceutical companies including Pfizer, Johnson & Johnson, Eli Lilly, and others. Within 30 days of enactment, the department must make this information available in a searchable, downloadable format, though it can withhold certain proprietary pricing information and data legally protected from disclosure while still documenting what was withheld. The bill also requires Congress and independent auditors to receive detailed reports on the released information and its economic effects on drug prices, Medicare, Medicaid, and healthcare competition. The legislation aims to increase transparency around confidential drug pricing negotiations and their impact on Americans' healthcare costs.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.